NASDAQ:ITRM
Iterum Therapeutics Plc Stock News
$1.54
-0.0500 (-3.14%)
At Close: Mar 28, 2024
Iterum Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024
04:30pm, Thursday, 21'st Mar 2024
DUBLIN, Ireland and CHICAGO, March 21, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral
Iterum (ITRM) Plans Early Submission of UTI Drug NDA, Stock Up
09:00am, Thursday, 07'th Mar 2024
Iterum (ITRM) stock rises as the company gears up to submit a regulatory application to the FDA seeking approval for oral sulopenem to treat adult women with uUTIs ahead of schedule.
Iterum Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on November 14, 2023
08:30am, Tuesday, 07'th Nov 2023
DUBLIN, Ireland and CHICAGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral
Iterum Therapeutics to Present Data at IDWeek 2023
09:15am, Thursday, 12'th Oct 2023
DUBLIN, Ireland and CHICAGO, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral
Iterum Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 11, 2023
05:00pm, Friday, 04'th Aug 2023
DUBLIN, Ireland and CHICAGO, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral
Iterum Therapeutics to Present Data at ASM Microbe 2023
06:23pm, Monday, 12'th Jun 2023
DUBLIN, Ireland and CHICAGO, June 12, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral
All You Need to Know About Iterum Therapeutics PLC (ITRM) Rating Upgrade to Strong Buy
01:39pm, Thursday, 13'th Apr 2023
Iterum Therapeutics PLC (ITRM) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term
Iterum Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023
05:00pm, Thursday, 09'th Mar 2023
DUBLIN, Ireland and CHICAGO, March 09, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral
Iterum Therapeutics plc (ITRM) Q3 2022 Earnings Call Transcript
11:42am, Thursday, 10'th Nov 2022
Iterum Therapeutics plc (NASDAQ:ITRM ) Q3 2022 Earnings Conference Call November 10, 2022 8:30 AM ET Company Participants Louise Barrett – Senior Vice President-Legal Affairs Corey Fishman – Chief
Iterum Therapeutics to Present Data at IDWeek 2022
05:19pm, Monday, 17'th Oct 2022
DUBLIN, Ireland and CHICAGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral
Iterum Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
09:15am, Wednesday, 07'th Sep 2022
DUBLIN, Ireland and CHICAGO, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral
Iterum Therapeutics (ITRM) Stock: 1-For-15 Reverse Split Goes Into Effect
08:42am, Thursday, 18'th Aug 2022
A 1-for-15 reverse split of Iterum Therapeutics (ITRM) shares have gone into effect. These are the details.
Iterum Therapeutics Announces Date of 1-for-15 Reverse Share Split
09:00pm, Tuesday, 16'th Aug 2022
DUBLIN, Ireland and CHICAGO, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation
Iterum Therapeutics Shares Are Surging - Read Why
02:40pm, Monday, 11'th Jul 2022
Iterum Therapeutics plc (NASDAQ: ITRM) has agreed with the FDA under the special protocol assessment (SPA) process on the design, endpoints, and statistical analysis of a Phase 3 trial for oral sul
Why Is Iterum Therapeutics (ITRM) Stock Up 73% Today?
11:14am, Monday, 11'th Jul 2022
Iterum Therapeutics (ITRM) stock is taking off on Monday as investors react to news of a clinical trial agreement with the FDA. The post Why Is Iterum Therapeutics (ITRM) Stock Up 73% Today?